Alpha-blocker, PDE-5 combo doesn't lead to CV events

Alpha-blocker, PDE-5 combo doesn't lead to CV events

Related Content:

Drug Therapy
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria